内容紹介
Promising Effects of Pregabalin in the Treatment of Oxaliplatin-Induced Sensory Neuropathy in Patients with Colorectal Carcinoma
Summary
Thirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin. All patients received oxaliplatin as adjuvant or first-line chemotherapy. The mFOLFOX6 and CapeOX groups included 3 and 10 cases, respectively, and the average treatment regimens were 8 and 5 doses, respectively. Before receiving pregabalin, sensory neuropathy was classified as Grade 3 in 2 patients, as Grade 2 in 8 patients, and as Grade 1 in 3 patient. The average amount of pregabalin administered to patients was 237 (range: 150-450) mg. After administering pregabalin, we observed improvements in 8 neuropathy cases(61.5%)within approximately 2 weeks. All side effects were mild. In this study, pregabalin was shown to positively impact sensory neuropathy resulting from oxaliplatin treatment and to enable the long-term use of oxaliplatin-based chemotherapy.
要旨
進行・再発大腸癌でoxaliplatin投与中もしくは投与歴のある末梢神経障害を認める13症例につき,pregabalin投与前後でのGradeを比較検討した。13例とも一次治療もしくは術後補助療法にoxaliplatinを投与していた。使用レジメンはmFOLFOX6が3例,CapeOXが10例であった。平均投与回数はFOLFOX 8回,CapeOXでは5回であった。pregabalin投与時の末梢神経障害はGrade 3が2例,Grade 2が8例,Grade 1が3例であり,平均投与量は237(150～450)mg。投与後はほぼ2週間以内に効果が認められ,改善を認めたものは8例(61.5%)であった。副作用は肝機能異常1例,眠気1例,ふらつき2例,下痢を1例認めたが,いずれも軽度であった。今回の検討では,pregabalinはoxaliplatin使用後の末梢神経障害に効果があり,oxaliplatinの長期使用を可能にすることが示唆された。
目次
Summary
Thirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin. All patients received oxaliplatin as adjuvant or first-line chemotherapy. The mFOLFOX6 and CapeOX groups included 3 and 10 cases, respectively, and the average treatment regimens were 8 and 5 doses, respectively. Before receiving pregabalin, sensory neuropathy was classified as Grade 3 in 2 patients, as Grade 2 in 8 patients, and as Grade 1 in 3 patient. The average amount of pregabalin administered to patients was 237 (range: 150-450) mg. After administering pregabalin, we observed improvements in 8 neuropathy cases(61.5%)within approximately 2 weeks. All side effects were mild. In this study, pregabalin was shown to positively impact sensory neuropathy resulting from oxaliplatin treatment and to enable the long-term use of oxaliplatin-based chemotherapy.
要旨
進行・再発大腸癌でoxaliplatin投与中もしくは投与歴のある末梢神経障害を認める13症例につき,pregabalin投与前後でのGradeを比較検討した。13例とも一次治療もしくは術後補助療法にoxaliplatinを投与していた。使用レジメンはmFOLFOX6が3例,CapeOXが10例であった。平均投与回数はFOLFOX 8回,CapeOXでは5回であった。pregabalin投与時の末梢神経障害はGrade 3が2例,Grade 2が8例,Grade 1が3例であり,平均投与量は237(150～450)mg。投与後はほぼ2週間以内に効果が認められ,改善を認めたものは8例(61.5%)であった。副作用は肝機能異常1例,眠気1例,ふらつき2例,下痢を1例認めたが,いずれも軽度であった。今回の検討では,pregabalinはoxaliplatin使用後の末梢神経障害に効果があり,oxaliplatinの長期使用を可能にすることが示唆された。